Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies

. 2020 Oct ; 55 (10) : 1996-2007. [epub] 20200320

Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid32203268
Odkazy

PubMed 32203268
PubMed Central PMC7515850
DOI 10.1038/s41409-020-0869-6
PII: 10.1038/s41409-020-0869-6
Knihovny.cz E-zdroje

Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppressive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively evaluated the safety and efficacy of treosulfan-based conditioning in children with hematological malignancies in this phase II trial. Overall, 65 children with acute lymphoblastic leukemia (35.4%), acute myeloid leukemia (44.6%), myelodysplastic syndrome (15.4%), or juvenile myelomonocytic leukemia (4.6%) received treosulfan intravenously at a dose of 10 mg/m2/day (7.7%), 12 g/m2/day (35.4%), or 14 g/m2/day (56.9%) according to their individual body surface area in combination with fludarabine and thiotepa. The incidence of complete donor chimerism at day +28 was 98.4% with no primary and only one secondary graft failure. At 36 months, NRM was only 3.1%, while relapse incidence was 21.7%, and overall survival was 83.0%. The cumulative incidence of acute graft-vs.-host disease was 45.3% for grades I-IV and 26.6% for grades II-IV. At 36 months, 25.8% overall and 19.4% moderate/severe chronic graft-vs.-host disease were reported. These data confirm the safe and effective use of treosulfan-based conditioning in pediatric patients with hematological malignancies. Therefore, treosulfan/fludarabine/thiotepa can be recommended for myeloablative conditioning in children with hematological malignancies.

Children's Hospital Regina Margherita University of Turin Turin Italy

Children's Hospital University of Erlangen Erlangen Germany

Department for Children and Adolescents Division for Stem Cell Transplantation Immunology and Intensive Care Medicine Goethe University Frankfurt Germany

Department of Pediatric Hematology and Oncology Collegium Medicum UMK Torun Bydgoszcz Poland

Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic

Department of Pediatric Hematology Oncology and BMT University Hospital Muenster Muenster Germany

Department of Pediatric Hematology Oncology and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

Department of Pediatric Hematology Oncology and Transplantology Medical University of Lublin Lublin Poland

Department of Pediatrics Hannover Medical School Hannover Germany

Department of Pediatrics Jena University Hospital Jena Germany

Depertment of Pediatrics 3 University Hospital of Essen Essen Germany

Great Ormond Street Hospital London UK

IRCCS Bambino Gesú Children's Hospital Sapienza University of Rome Rome Italy

medac GmbH Wedel Germany

Medical College University Children's Hospital in Cracow Jagiellonian University Cracow Poland

Sheffield Children's Hospital Sheffield UK

University Children's Hospital Heidelberg Heidelberg Germany

University Children's Hospital of Wuerzburg Wuerzburg Germany

University Hospital of Regensburg Regensburg Germany

University Medical Center Hamburg Eppendorf Hamburg Germany

Zobrazit více v PubMed

Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140:610–24. doi: 10.1111/j.1365-2141.2007.06958.x.. PubMed DOI

Peters C, Schrappe M, Stackelberg A, von Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265–74. doi: 10.1200/JCO.2014.58.9747.. PubMed DOI

Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M, et al. Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplant. 2013;48:651–6. doi: 10.1038/bmt.2012.204.. PubMed DOI

Balduzzi A, Valsecchi MG, Silvestri D, Locatelli F, Manfredini L, Busca A, et al. Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant. 2002;29:93–100. doi: 10.1038/sj.bmt.1703337.. PubMed DOI

Bresters D, van Gils ICM, Kollen WJW, Ball LM, Oostdijk W, van der Bom JG, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant. 2010;45:79–85. doi: 10.1038/bmt.2009.92.. PubMed DOI

Shimoni A, Labopin M, Savani B, Hamladji R-M, Beelen D, Mufti G, et al. Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2018;24:751–7. doi: 10.1016/j.bbmt.2017.12.776.. PubMed DOI

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, et al. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2017;123:2671–9. doi: 10.1002/cncr.30646.. PubMed DOI

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica. 2011;96:1344–50. doi: 10.3324/haematol.2011.043810.. PubMed DOI PMC

Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, et al. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL) Bone Marrow Transplant. 2015;50:1503–7. doi: 10.1038/bmt.2015.202.. PubMed DOI

Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103:725–31. doi: 10.1182/blood-2002-11-3615.. PubMed DOI

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2019:e28–39. 10.1016/S2352-3026(19)30157-7. PubMed DOI

Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24:529–36. doi: 10.1016/j.bbmt.2017.11.009.. PubMed DOI

Burroughs LM, Shimamura A, Talano J-A, Domm JA, Baker KK, Delaney C, et al. Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transplant. 2017;23:1669–77. doi: 10.1016/j.bbmt.2017.06.002.. PubMed DOI PMC

Marzollo A, Calore E, Tumino M, Pillon M, Gazzola MV, Destro R, et al. Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease. Mediterr J Hematol Infect Dis. 2017;9:e2017014. doi: 10.4084/MJHID.2017.014.. PubMed DOI PMC

Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A-M, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440–8. doi: 10.1182/blood-2016-03-704015.. PubMed DOI PMC

Slatter MA, Boztug H, Pötschger U, Sykora K-W, Lankester A, Yaniv I, et al. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50:1536–41. doi: 10.1038/bmt.2015.171.. PubMed DOI

Strocchio L, Zecca M, Comoli P, Mina T, Giorgiani G, Giraldi E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015;169:726–36. doi: 10.1111/bjh.13352.. PubMed DOI

Dinur-Schejter Y, Krauss AC, Erlich O, Gorelik N, Yahel A, Porat I, et al. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning. Pediatr Blood Cancer. 2015;62:299–304. doi: 10.1002/pbc.25267.. PubMed DOI

Maschan M, Shelikhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant. 2016;51:668–74. doi: 10.1038/bmt.2015.343.. PubMed DOI

Boztug H, Sykora K-W, Slatter M, Zecca M, Veys P, Lankester A, et al. European Society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2016;63:139–48. doi: 10.1002/pbc.25764.. PubMed DOI

Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120:473–6. doi: 10.1182/blood-2012-04-423822.. PubMed DOI

van der Stoep MYEC, Bertaina A, Brink MHten, Bredius RG, Smiers FJ, Wanders DCM, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179:772–80. doi: 10.1111/bjh.14960.. PubMed DOI

Romański M, Wachowiak J, Główka FK. Treosulfan pharmacokinetics and its variability in pediatric and adult patients undergoing conditioning prior to hematopoietic stem cell transplantation: current state of the art, in-depth analysis, and perspectives. Clin Pharmacokinet. 2018;57:1255–65. doi: 10.1007/s40262-018-0647-4.. PubMed DOI PMC

Chiesa R, Standing JF, Winter R, Nademi Z, Chu J, Pinner D, et al. Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial. Clin Pharmacol Ther. 2019. 10.1002/cpt.1715. PubMed PMC

van der Stoep MYEC, Zwaveling J, Bertaina A, Locatelli F, Guchelaar HJ, Lankester AC, et al. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. Br J Clin Pharm. 2019;85:2033–44. doi: 10.1111/bcp.13995.. PubMed DOI PMC

Reijmers T, Hemmelmann C, Sykora K-W, Vora A, Kehne J, Möller A-K, et al. Population PK-modelling of treosulfan in paediatric allogeneic transplant patients. Twenty-seventh Annual Meeting of the Population Approach Group in Europe (page), Montreux; 2018.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai H-L, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102:391–400. doi: 10.3324/haematol.2016.144139.. PubMed DOI PMC

Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83. doi: 10.1097/00007890-198712000-00011. PubMed DOI

Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–8. doi: 10.1200/JCO.1988.6.10.1562.. PubMed DOI

Maiolica A, Meunier L, Bialleck S, Guhde I, Wood S, Struwe P. Bioanalytical determination of treosulfan and its active metabolites. EBF 7th Open Meeting, Barcilona; 2014.

Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, et al. Treosulfan, fludarabine, and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: prospective phase II trial of the pediatric blood and marrow transplant consortium. Biol Blood Marrow Transplant. 2018;24:1651–6. doi: 10.1016/j.bbmt.2018.04.025.. PubMed DOI PMC

Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410–9. doi: 10.1182/blood-2004-05-1944.. PubMed DOI

Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, et al. Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the pediatric disease working party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:467–74. doi: 10.1016/j.bbmt.2016.11.022.. PubMed DOI

Strahm B, Nöllke P, Zecca M, Korthof ET, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25:455–62. doi: 10.1038/leu.2010.297.. PubMed DOI

Bartelink IH, van Reij EML, Gerhardt CE, van Maarseveen EM, Wildt A, de, Versluys B, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. 2014;20:345–53. doi: 10.1016/j.bbmt.2013.11.027.. PubMed DOI

European Medicines Agency. Union register of medicinal products: marketing authorisation. Decision number (2019)4858 of 20 Jun 2019. 2019. https://ec.europa.eu/health/documents/community-register/html/h1351.htm.

Zobrazit více v PubMed

EudraCT
2013–003604–39

ClinicalTrials.gov
NCT02333058

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...